Lorbrena (lorlatinib)

pCPA File Number: 22304
Negotiation Status:
Concluded with an LOI
Indication(s):
for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)
Sponsor/Manufacturer:
Pfizer Canada ULC
CADTH Project Number:
PC0249
pCPA Engagement Letter Issued:
Negotiation Process Concluded: